Presentation is loading. Please wait.

Presentation is loading. Please wait.

Age, cytomegalovirus (CMV) seropositivity in the healthy and type 2 diabetes mellitus (T2DM) and the response to influenza vaccination after the CMV serostatus.

Published byÖdön Fodor Modified over 5 years ago

Similar presentations

Presentation on theme: "Age, cytomegalovirus (CMV) seropositivity in the healthy and type 2 diabetes mellitus (T2DM) and the response to influenza vaccination after the CMV serostatus."— Presentation transcript:

1 Age, cytomegalovirus (CMV) seropositivity in the healthy and type 2 diabetes mellitus (T2DM) and the response to influenza vaccination after the CMV serostatus in healthy and patients with T2DM. Age, cytomegalovirus (CMV) seropositivity in the healthy and type 2 diabetes mellitus (T2DM) and the response to influenza vaccination after the CMV serostatus in healthy and patients with T2DM. (A) Comparison of the age for CMV+ and CMV− elderly participants. No difference was found. (B) Distribution of the CMV− and CMV+ participants in the non-T2DM and T2DM elderly groups. No difference was found. (C) Hemagglutination inhibition assay (HIA) ratio day 28/day 0 (d28/d0) between the total CMV+ and CMV− elderly populations, which were significantly different (p<0.0251). (D) HIA ratio d28/d0 between CMV− and CMV+ participants in the non-T2DM and the T2DM elderly groups. CMV+ participants had significantly higher ratio (p<0.0482). Janet E McElhaney et al. BMJ Open Diab Res Care 2015;3:e000140 ©2015 by American Diabetes Association

Download ppt "Age, cytomegalovirus (CMV) seropositivity in the healthy and type 2 diabetes mellitus (T2DM) and the response to influenza vaccination after the CMV serostatus."

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p
Dandan Wang et al. BTS 2018;3:350-362 Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.
Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.

Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.
Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)

Engagement in recommended behaviors to prevent type 2 Diabetes (n=82)
Predicted probability of type 2 diabetes by age and four metabolic phenotypes, from logistic regression: Cameron County Hispanic Cohort (CCHC) and Population.

Predicted probability of type 2 diabetes by age and four metabolic phenotypes, from logistic regression: Cameron County Hispanic Cohort (CCHC) and Population.
Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.
Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),

Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

Flow sheet over the primary study population as well as comparative individuals of “pre-diabetic” individuals followed from HUNT2 to HUNT3 (GAD, glutamic.

Similar presentations

Ads by Google